Immunovant, Inc.

NASDAQ: IMVT · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001764013Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 56DQ —GM —SS 69

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, market scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

$7.1M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$505.6M

Employees

315

as of 2026-08-06

Market cap

$8.1B

as of 2026-08-06

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$505.6M-$505.6M2026

Total assets$957.0M$957.0M2026

Liabilities$104.4M$104.4M2026

Equity$852.6M$852.6M2026

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Immunovant, Inc.’s financial profile?

Immunovant, Inc. earned -$505.6M in FY2026 net income.

Peers · Healthcare

Heart Tronics, Inc.——Nuvalent, Inc.——Apogee Therapeutics, Inc.——Vaxcyte, Inc.——Belite Bio, Inc——Erasca, Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOEric Venker

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: IMVT

Employees315

IPO date2019-06-21

Latest filings

10-Q2026-08-06 8-K2026-08-06 DEF 14A2026-07-22 10-K2026-05-20 8-K2026-05-20 8-K2026-02-06 10-Q2026-02-06 8-K2025-12-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.